<abstract xmlns="http://www.w3.org/1999/xhtml"><p>We present tooth extraction in a patient treated with bisphosphonates (BPs) for cancer and at risk of osteonecrosis of the jaw. The administration of platelet-rich fibrin (PRF) is an innovative method of promoting wound healing that allows hermetic closure at the surgical site after extraction without mucoperiosteal flaps or periosteal release sections. Here, we describe the case of a 60-year-old man who had osteonecrosis of the upper jaw and underwent surgery for prostate cancer in 2012. In 2014, bone metastases were detected, and the patient was treated with Xgeva and Zometa: a two-year therapy with Xgeva, followed by treatment with Zometa. In 2018, after extraction of a tooth in the upper right jaw, a healing wound of extraction and stripping of the maxillary bone occurred. The patient was admitted for hospital treatment and underwent surgery to remove the osteonecrotic lesion, sequester and administer PRF (platelet-rich fibrin), and sew tightly. As a result of the treatment, complete re-epithelialization of the wound without infection occurred. Generally, in more invasive surgical procedures, the use of PRF to close the wells after extraction in patients receiving BP appears to be a promising alternative. Additional clinical trials will be essential t to clarify the effectiveness of PRF in preventing BP-related osteonecrosis after tooth extraction.</p></abstract>

We present tooth extraction in a patient treated with bisphosphonates (BPs) for cancer and at risk of osteonecrosis of the jaw. The administration of platelet-rich fibrin (PRF) is an innovative method of promoting wound healing that allows hermetic closure at the surgical site after extraction without mucoperiosteal flaps or periosteal release sections. Here, we describe the case of a 60-year-old man who had osteonecrosis of the upper jaw and underwent surgery for prostate cancer in 2012. In 2014, bone metastases were detected, and the patient was treated with Xgeva and Zometa: a two-year therapy with Xgeva, followed by treatment with Zometa. In 2018, after extraction of a tooth in the upper right jaw, a healing wound of extraction and stripping of the maxillary bone occurred. The patient was admitted for hospital treatment and underwent surgery to remove the osteonecrotic lesion, sequester and administer PRF (platelet-rich fibrin), and sew tightly. As a result of the treatment, complete re-epithelialization of the wound without infection occurred. Generally, in more invasive surgical procedures, the use of PRF to close the wells after extraction in patients receiving BP appears to be a promising alternative. Additional clinical trials will be essential t to clarify the effectiveness of PRF in preventing BP-related osteonecrosis after tooth extraction.

Use of Platelet-Rich Fibrin for Jaw Osteonecrosis: A Case Report

Department of Imaging Diagnostics, Dental Allergology and Physical Therapy, Faculty of Dental Medicine

Department of Epidemiology and Disaster Medicine, Faculty of Public Health

Department of Oral Surgery, Faculty of Dental Medicine

Journal of Biomedical and Clinical Research

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Use of Platelet-Rich Fibrin for Jaw Osteonecrosis: A Case Report"}

We present tooth extraction in a patient treated with bisphosphonates (BPs) for cancer and at risk of osteonecrosis of the jaw. The administration of...

Use of Platelet-Rich Fibrin for Jaw Osteonecrosis: A Case Report

Published Online: Jan 21, 2021

Page range: 139 - 139

Received: Feb 10, 2020

Accepted: Dec 11, 2020

DOI: https://doi.org/10.2478/jbcr-2020-0020

Keywords
bisphosphonates, osteonecrosis, platelet-rich fibrin, oral medicine

© 2020 Petya G. Kanazirska et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Use of Platelet-Rich Fibrin for Jaw Osteonecrosis: A Case Report

Published Online: Jan 21, 2021

Page range: 139 - 139

Received: Feb 10, 2020

Accepted: Dec 11, 2020

DOI: https://doi.org/10.2478/jbcr-2020-0020

Keywordsbisphosphonates, osteonecrosis, platelet-rich fibrin, oral medicine

© 2020 Petya G. Kanazirska et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Keywords
bisphosphonates, osteonecrosis, platelet-rich fibrin, oral medicine